Described herein are methods and compositions for treatment of diabetes and/or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract said signaling related hormones such as glucagon like peptide 1 (GLP 1) and peptide tyrosine tyrosine (PYY) that involve inhibition of gastric emptying and appetite. As a novel way to treat diabetes with limited adverse effects the described invention uses body s own endocrine system to treat diabetes which is an advantage over current therapies that may simply provide disease management without cure or require more radical approaches such as surgical intervention
